Differential effects of raloxifene and continuous combined hormone replacement therapy on biochemical markers of cardiovascular risk: results from the Euralox 1 study

References

• Barrett-Connor E, Grady D. Hormone replace-ment therapy, heart disease, and other consider-ations. Annu Rev Public Health 1998;19:55–72
   Google Scholar
• Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary pre-vention of coronary heart disease in postmeno-pausal women. J Am Med Assoc 1998;280: 605–13
   PubMed Web of Science ®Google Scholar
• Herrington DM, Reboussin DM, Brosnihan B, et al. Effects of estrogen replacement on the pro-gression of coronary artery atherosclerosis. N Engl J Med 2000;343:522–9
   PubMed Web of Science ®Google Scholar
• Larkin M. Ups and downs for HRT and heart disease. Lancet 2000;355:1338
   Web of Science ®Google Scholar
• Falkeborn M, Persson I, Adami HO, et al. The risk of acute myocardial infarction after oestro-gen and oestrogen—progestogen replacement. Br J Obstet Gynaecol 1992;99:821–8
   PubMedGoogle Scholar
• Mann RD, Lis Y, Chikwujindu J, Chanter DO. A study of the association between hormonereplacement therapy, smoking and the occur-rence of myocardial infarction in women. J Clin Epidemiol 1994;47:307–12
   PubMed Web of Science ®Google Scholar
• Thompson SG, Meade TW, Greenberg G. The use of hormonal replacement therapy and the risk of stroke and myocardial infarction in women. J Epidemiol Community Health 1989; 43:173–8
   Google Scholar
• Voigt LF, Weiss NS, Chu J, Dating JR, McKnight B, van Belle G. Progestagen supplementation of exogenous estrogens and risk of endometrial cancer. Lancet 1991;338:274–7
   Google Scholar
• Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmeno-pausal estrogen replacement on the concentra-tions and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196–204
   PubMed Web of Science ®Google Scholar
• The Writing Group of the PEP Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. J Am Med Assoc 1995;273:199–208
   Google Scholar
• Rijpkema AHM, van der Sanden AA, Ruijs AHC. Effects of post-menopausal oestrogen—progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990;12: 259–85
   PubMed Web of Science ®Google Scholar
• Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7
   PubMed Web of Science ®Google Scholar
• Ettinger B, Black DM, Mitlak BH, et al. Reduc-tion of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxi-fene: results from a 3-year randomized clinical trial. J Am Med Assoc 1999;282:637–45
   PubMed Web of Science ®Google Scholar
• Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. J Am Med Assoc 1999;281: 2189–97
   PubMed Web of Science ®Google Scholar
• Boss SM, Huster WJ, Neild JA, Glant MA, Eisenhut CC, Draper MW. Effects of raloxifene hydrochloride on the endometrium of postmeno-pausal women. Am J Obstet Gynecol 1997;177: 1458–64
   PubMed Web of Science ®Google Scholar
• Davies GC, Huster WJ, Shen W, et al. Endo-metrial response to raloxifene compared with placebo, cyclical hormone replacement therapy, and unopposed estrogen in postmenopausal women. Menopause 1999;6:188–95
   PubMed Web of Science ®Google Scholar
• Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. J Am Med Assoc 1998;279:1445–51
   PubMed Web of Science ®Google Scholar
• Kauffman RF, Bean JS, Fahey KJ, Cullinan GJ, Cox DA, Bensch WR. Raloxifene and estrogeninhibit intimal thickening in response to balloon injury in carotid arteries of male and ovari-ectomized female rats. J Cardiovasc Pharmacol 2000;36:459–65
   PubMed Web of Science ®Google Scholar
• Figtree GA, Lu YQ, Webb CM, Collins P. Raloxifene acutely relaxes coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 1999;100:1095–101
   PubMed Web of Science ®Google Scholar
• Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Knadler MP, Christiansen C. Raloxifene reduces atherosclerosis: studies of optimized raloxifene doses in ovariectomized, cholesterol-fed rabbits. Clin Endocrinol 2000;52:225–33
   PubMed Web of Science ®Google Scholar
• Zoma WD, Baker RS, Clark KE. Coronary and uterine responses to raloxifene in the sheep. Am J Obstet Gynecol 2000;182:521–8
   PubMed Web of Science ®Google Scholar
• Zuckerman SH, Bryan N. Inhibition of LDL oxi-dation and myeloperoxidase dependent tyrosyl radical formation by the selective estrogen recep-tor modulator raloxifene (LY 139481 HCL). Atherosclerosis 1996;126:65–75
   PubMed Web of Science ®Google Scholar
• Clarkson TB, Anthony MS, Jerome CP. Lack of effect of raloxifene on coronary artery athero-sclerosis of postmenopausal monkeys. J Clin Endocrinol Metab 1998;83:721–6
   Google Scholar
• Sarrel PM, Nawaz H, Chan W, Fuchs M, Katz DL. Raloxifene improves brachial artery and microcirculatory flow-mediated dilation in healthy postmenopausal women. Presented at the Annual Meeting of the American Heart Associa-tion, New Orleans, November 2000:abstr 47150
   Google Scholar
• Wren BG, Brown L. Compliance with hormone replacement therapy. Maturitas 1991;13:17–21
   PubMed Web of Science ®Google Scholar
• Clauss A. Gerinnungsphysiologische Schnell-methode zur Bestimmung des Fibrinogens. Acta Haematol 1957;17:237–46
   PubMedGoogle Scholar
• Shao J. Consistency of jackknife variance estima-tors. Statistics 1996;22:49–57
   Google Scholar
• Efron B, Stein C. The jackknife estimate of vari-ance. Ann Stat 1981;9:586–96
   Web of Science ®Google Scholar
• Campbell MJ, Gardner MJ. Calculating confi-dence intervals for some non-parametric analy-ses. Br Med J 1988;296:1454–6
   PubMed Web of Science ®Google Scholar
• Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteo-porosis with raloxifene: a randomized trial. J Bone Miner Res 1998;13:1747–54
   PubMed Web of Science ®Google Scholar
• Meunier PJ, Vignot E, Garnero P, et al. Treat-ment of postmenopausal women with osteo-porosis or low bone density with raloxifene. Osteoporosis Int 1999;10:330–6
   PubMed Web of Science ®Google Scholar
• Jensen J, Riis BJ, Strom V, Christiansen C. Long-term withdrawal effects of two different oestrogen—progestogen combinations on lipid and lipoprotein profiles in post-menopausal women. Maturitas 1989;11:117–28
   PubMed Web of Science ®Google Scholar
• Tilly-Kiesi M, Kahri J, Pyörälä J, et al. Responses of HDL subclasses, Lp(A-I) and Lp(A-II: A-I) levels and lipolytic enzyme activities to continu-ous oral estrogen—progestin and transdermal estrogen with cyclic progestin regimens in post-menopausal women. Atherosclerosis 1997;129: 249–59
   Google Scholar
• Alexandersen P, Byrjalsen I, Christiansen C. Piperazine oestrone sulphate and interrupted norethisterone in postmenopausal women: effects on bone mass, lipoprotein metabolism, climacteric symptoms, and adverse effects. Br J Obstet Gynaecol 2000;107:356–64
   Google Scholar
• Mandour T, Kissebah AH, Wynn V. Mechanism of hypertriglyceridaemia associated with contra-ceptive steroids. Horm Metab Res 1973;5: 184–90
   PubMedGoogle Scholar
• Walsh BW, Sacks FM. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism. J Clin Invest 1993;91:2126–32
   PubMed Web of Science ®Google Scholar
• Sacks FM, Walsh BW. Sex hormones and lipo-protein metabolism. Curr Opin Lipidol 1994;5: 236–40
   PubMedGoogle Scholar
• Kannel WB. Metabolic risk factors for coronary heart disease in women: perspective from the Framingham Study. Am Heart J 1987;114: 413–19
   PubMed Web of Science ®Google Scholar
• Task Force on Oral Contraceptives. A multi-centre study of coagulation and haemostatic vari-ables during oral contraception: variations with four formulations. Br J Obstet Gynaecol 1991; 98:1117–28
   PubMedGoogle Scholar
• Norris LA, Bonnar J. The effect of oestrogen dose and progestogen type on haemostatic changes in women taking low dose oral contraceptives. Br J Obstet Gynaecol 1996;103:261–7
   PubMedGoogle Scholar
• Teede HJ, McGrath BP, Smolich JJ, et al. Postmenopausal hormone replacement therapy increases coagulation activity and fibrinolysis. Arteriosc Thromb Vasc Biol 2000;20:1404–9
   PubMed Web of Science ®Google Scholar
• Pornel B, Rio M. Oral 170-estradiol and nor-ethisterone acetate as replacement therapy improves the lipid cardiovascular risk factors. Gynaecol Endocrinol 1988;2(Suppl 2):240
   Google Scholar
• Cushman M, Legault C, Barrett-Connor E, et al. Effect of postmenopausal hormones on inflam-mation sensitive proteins: the Postmenopausal Estrogen/Progestin Interventions (PEP!) Study. Circulation 1999;100:893–9
   Google Scholar
• Van Baal WM, Kenemans P, van der Mooren MJ, Kessel H, Emeis IJ, Stehouwer CDA. Increased C-reactive protein levels during short-term hormone replacement therapy in healthy post-menopausal women. Thromb Haemost 1999;81: 925–8
   Google Scholar
• Walsh BW, Paul S, Wild R, et al. The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, con-trolled trial. J Clin Endocrinol Metab 2000;85: 214–18
   PubMed Web of Science ®Google Scholar
• Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C. Raloxifene lowers serum lipoprotein(a) in healthy postmeno-pausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens. Menopause 1999;6:134–7
   Google Scholar
• Barrett-Connor E, Wenger NK, Grady D, et al. Coronary heart disease in women, randomized, clinical trials, HERS and RUTH. Maturitas 1998; 31:1–7
   Google Scholar